Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 10/20 | 0.55 |
| ▸ | CHUK | O15111 | 6/20 | 0.41 |
| ▸ | TTBK1 | Q5TCY1 | 3/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18828060 | 0.91 | MAP3K14 (0.59) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205405 | 0.91 | MAP3K14 (0.59) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205455 | 0.90 | MAP3K14 (0.57) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205529 | 0.85 | MAP3K14 (0.55) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205655 | 0.82 | MAP3K14 (0.54) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205531 | 0.81 | MAP3K14 (0.60) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205394 | 0.80 | MAP3K14 (0.70) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205535 | 0.79 | MAP3K14 (0.47) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205627 | 0.79 | MAP3K14 (0.59) | MAP3K14CHUKTTBK1 | |
| SCHEMBL16205416 | 0.79 | MAP3K14 (0.56) | MAP3K14CHUKTTBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643964-B2 | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-09 | — | — | US | disclosed |
| US-9643964-B2 | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-09 | — | — | US | disclosed |
| US-20160075699-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-03-17 | — | — | US | disclosed |
| WO-2014174021-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075699-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | NFKBIA, IKBKG, MAP3K14 | MAP3K14 3/4885CHUK 25/4885TTBK1 485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.